Vaginal Cancer Clinical Trial
Official title:
Evaluating the Immune Persistence of Recombination Quadrivalent HPV Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomized Clinical Trial
NCT number | NCT05371353 |
Other study ID # | 4-HPV-3003 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 14, 2022 |
Est. completion date | May 2027 |
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
Status | Recruiting |
Enrollment | 600 |
Est. completion date | May 2027 |
Est. primary completion date | May 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 9 Years to 45 Years |
Eligibility | Inclusion Criteria: - Subjects who participated in the phase III clinical trial of non inferior efficacy of HPV tetravalent vaccine of Yangchun Center for Disease Control and Prevention (protocol No.: 4-HPV-3001), completed three doses of HPV quadrivalent vaccine and provided blood sample at months 7; Or subjects who have participated in the bridging study of HPV quadrivalent vaccine of Mianyang Center for Disease Control and Prevention (scheme No.: 4-HPV-3002), completed the whole vaccine schedule at month 0,2,6, and provided blood sample at months 7; - The subjects aged 9 to 17 years old at Mianyang site and their legal guardian should provide legal indentification; the subjects aged over 18 years old should provide legal indentification; - The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form; - Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements. Exclusion Criteria: - Enrolling or plan to enroll in other clinical trials (drugs or vaccines) (except that the observational clinical study and the subjects at Mianyang site are still in the post exemption safety follow-up stage of the 4-HPV-3002 trial); - Suffering from thrombocytopenia or any coagulation dysfunction that can be a contraindication to blood collection (such as coagulation factor deficiency, coagulation diseases, platelet abnormalities, etc.); - According to the investigator's judgment, the subject has any condition may interfere with process of evaluation of immune persistence. |
Country | Name | City | State |
---|---|---|---|
China | Center for Disease Control and Prevention | Mianyang | Sichuan |
China | Yangchun Center For Disease Prevention And Control | Yangchun | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Shanghai Bovax Biotechnology Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Seroconversion rate (SCR) for Each of the HPV Types Contained in the Vaccine | The primary immue persistence outcome to evaluate respinses quadrivalent HPV vaccine was Year 5 seroconversion rate against HPV-types 6,11,16, and 18 | Month 12 | |
Primary | SCR for Each of the HPV Types Contained in the Vaccine | The primary immue persistence outcome to evaluate respinses quadrivalent HPV vaccine was Year 5 seroconversion rate against HPV-types 6,11,16, and 18 | Month 24 | |
Primary | SCR for Each of the HPV Types Contained in the Vaccine | The primary immue persistence outcome to evaluate respinses quadrivalent HPV vaccine was Year 5 seroconversion rate against HPV-types 6,11,16, and 18 | Month 36 | |
Primary | SCR for Each of the HPV Types Contained in the Vaccine | The primary immue persistence outcome to evaluate respinses quadrivalent HPV vaccine was Year 5 seroconversion rate against HPV-types 6,11,16, and 18 | Month 48 | |
Primary | SCR for Each of the HPV Types Contained in the Vaccine | The primary immue persistence outcome to evaluate respinses quadrivalent HPV vaccine was Year 5 seroconversion rate against HPV-types 6,11,16, and 18 | Month 60 | |
Primary | Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine | The primary immune persistence endpoint is anti-HPV type 6,11,16,and 18 antibody GMTs 5 years post dose 1 assessed among the subjects who were seropositive at Month 7 | Month 12 | |
Primary | GMTs for Each of the HPV Types Contained in the Vaccine | The primary immune persistence endpoint is anti-HPV type 6,11,16,and 18 antibody GMTs 5 years post dose 1 assessed among the subjects who were seropositive at Month 7 | Month 24 | |
Primary | GMTs for Each of the HPV Types Contained in the Vaccine | The primary immune persistence endpoint is anti-HPV type 6,11,16,and 18 antibody GMTs 5 years post dose 1 assessed among the subjects who were seropositive at Month 7 | Month 36 | |
Primary | GMTs for Each of the HPV Types Contained in the Vaccine | The primary immune persistence endpoint is anti-HPV type 6,11,16,and 18 antibody GMTs 5 years post dose 1 assessed among the subjects who were seropositive at Month 7 | Month 48 | |
Primary | GMTs for Each of the HPV Types Contained in the Vaccine | The primary immune persistence endpoint is anti-HPV type 6,11,16,and 18 antibody GMTs 5 years post dose 1 assessed among the subjects who were seropositive at Month 7 | Month 60 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Completed |
NCT02096783 -
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
|
N/A | |
Completed |
NCT02058550 -
Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
|
Phase 1 | |
Completed |
NCT01399658 -
Image-Guided Gynecologic Brachytherapy
|
Phase 2 | |
Completed |
NCT00581646 -
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
|
N/A | |
Completed |
NCT00528034 -
Lymphoscintigraphy in Patients With Vaginal Cancer
|
N/A | |
Completed |
NCT03158220 -
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
|
Phase 3 | |
Completed |
NCT05372016 -
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Recruiting |
NCT05743517 -
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
|
N/A | |
Recruiting |
NCT05027776 -
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
|
Phase 3 | |
Recruiting |
NCT05979610 -
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
|
Phase 2 | |
Completed |
NCT03956498 -
Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy
|
N/A | |
Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT00520598 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
|
Phase 2 | |
Completed |
NCT00551187 -
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
|
Phase 2 | |
Terminated |
NCT00669422 -
ChemoFx® PRO - A Post-Market Data Collection Study
|
N/A | |
Completed |
NCT02280811 -
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
|
Phase 2 | |
Completed |
NCT03676101 -
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 1 | |
Active, not recruiting |
NCT00800644 -
Pelvic Fractures and Radiation Therapy for Cervical Cancer
|
||
Recruiting |
NCT06432478 -
3D Printed Custom Applicators for HDR BT (DISCO)
|
N/A |